Craft

Shionogi

Stock Price

¥2.2 K

2024-10-29

Market Capitalization

¥1.9 T

2024-10-29

Revenue

¥410.1 B

FY, 2024

Shionogi Summary

Company Summary

Overview
Shionogi (塩野義製薬株式会社) is a pharmaceutical company developing treatments for infectious, pain, and chronic liver diseases. It also aims to provide treatments in areas such as inflammatory pain, neuropathic pain, Alzheimer’s disease, and ADHD (attention deficit hyperactivity disorder).
Type
Public
Status
Active
Founded
1878
HQ
Osaka, JP | view all locations
Website
https://www.shionogi.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Isao Teshirogi

    Isao Teshirogi, Representative Director, President and CEO

    • Takuko Sawada

      Takuko Sawada, Director and Executive Vice President and Senior Vice President of Integrated disease care Division

      • Keiichi Ando

        Keiichi Ando, Independent Director

        • Hiroshi Ozaki

          Hiroshi Ozaki, Independent Director

          Operating MetricsView all

          Laboratories

          2

          FY, 2017

          Plants

          3
          50.0%

          FY, 2018

          Manufacturing Facilities

          4

          FY, 2018

          LocationsView all

          23 locations detected

          • Osaka, Osaka HQ

            Japan

            1-8, Doshomachi 3-chome, Chuo-ku

          • Florham Park, NJ

            United States

            300 Campus Dr

          • Beijing, Beijing Shi

            China

            Room 07, 20th Floor, Jinghui Building, No.118, Jianguo Road B, Chaoyang District

          • Hong Kong, Kowloon

            Hong Kong

            911-12, Silvercord Tower 2, 30 Canton Road, Tsim Sha Tsui, Kowloon

          • Amagasaki, Hyogo

            Japan

            1-3, Kuise Terajima 2-chome

          • Amagasaki, Hyogo

            Japan

            829-1 TonouchI

          and 17 others

          Shionogi Financials

          Summary Financials

          Revenue (H1, 2025)
          ¥214.0B
          Gross profit (H1, 2025)
          ¥194.6B
          Net income (H1, 2025)
          ¥82.9B
          Cash (H1, 2025)
          ¥303.4B
          EBIT (H1, 2025)
          ¥75.9B
          Enterprise value
          $1.6T

          Footer menu